News for Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals (VRCA) has experienced a trading halt with an announcement expected soon. Investors are eagerly awaiting updates that could provide clar

Verrica Pharmaceuticals reports a significant 32.8% increase in YCANTH sales for Q2 2025. Analysts project a substantial upside for VRCA shares, with an

Verrica Pharmaceuticals (VRCA) reported significant demand for its product, YCANTH, in the second quarter, achieving 13,434 dispensed applicator units. This rep

On May 14, 2025, Needham analyst Serge Belanger reaffirmed a "Hold" rating on Verrica Pharmaceuticals (VRCA). The analysis by Needham maintains its previous sta

Revenue: $3.4 million for the first quarter of 2025, primarily from YCANTH.Gross Product Margin: Approximately 88% for the first quarter of 2025.Cost of Produc

May 13, 2025 / 08:30PM GMTOperator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticalsâ First Quarter 2025 Corporate Update Conferen

Verrica Pharmaceuticals experiences a robust first quarter in 2025, driven by the demand for YCANTH. Analysts predict significant upside potential with

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsKevin Gardner - Managing...

”“ Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarte

Revenue: Achieved $3.4 million in revenue for Q1 2025, surpassing the estimated $2.51 million, driven by strong demand for YCANTH.YCANTH Demand: Dispensed over

Verrica Pharmaceuticals (VRCA) has announced its first-quarter revenue reaching $3.439 million, surpassing the anticipated $2.53 million. This increase is attri

WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics comp

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics co

**media[587784]**

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or the ”œCompany”) ( VRCA), a dermatology therapeutics co

**media[584439]**

**media[563735]**

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics co

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics com